As a high-tech company engaged in the biotechnology realm, Beijing Kinghark Pharmaceutical Co., Ltd. (Kinghawk for short http://www.kinghawk828.com/), founded in 1993, is stationed in the Beijing Economic and Technology Development Area and occupies a plot area of 6,000 square meters. So far, it has independently developed many genetic engineering antigens and monoclonal antibodies in succession, including contagion series, tumor series and biochemical series extracorporeal diagnosis reagents etc.

Despite the rapid development of the international biotechnologies, Kinghawk always ranks in the front of the biotechnology kingdom and gradually became a fairly influential company in this field. It undertakes some state-level key projects such as the AIDS confirmation reagent R&D project for the Health Ministry of China and biological antiterrorism projects for the government. It has successfully built up domestically advanced operating platform, which integrates information collection, scientific research, production and sale into one, and successively set up extensive technical exchange and cooperation relationship with scores of enterprises located in Europe, North America, Japan and Australia etc. Besides, it also keeps good business relationship with many domestic blood stations, hospitals and scientific research institutes. As a result, Kinghawk maintains satisfying business growth.